고지방식 사료를 섭취한 어린 쥐에서 Topiramate가 체중 증가 및 혈중 인슐린과 렙틴 농도에 미치는 영향

Effects of Topiramate on Body Weight and Serum Levels of Insulin and Leptin in Young Rats Fed a High Fat Diet

Purpose : Topiramate is an antiepileptic drug used widely in the treatment of epil- epsy. It has also been reported to reduce body weight in humans and is currently used for eating disorders and obesity; little is known about the mechanism by which this drug induces weight loss. This study was carried out to investigate the effects of topiramate on weight and serum levels of insulin and leptin in young rats fed high fat diet (HFD). Methods : Forty male Wistar rats (4 weeks old) were randomly divided into four groups (diet, regular diet and high fat diet, treatment, topiramate and placebo). Topi- ramate (50 mg/kg/day) was orally administered via gastric gavage twice a day for 4 weeks. Food intake and body weight were monitored throughout the study. After 4 weeks, the plasma levels of glucose, triglycerides, free fatty acids, leptin, and insulin were determined. Results :We found significant reduction in body weight gain after topiramate admi- nistration in the HFD group (topiramate, 351.6 ± 28.6g; placebo, 397.6 ± 28.4g) (P < 0.05). Topiramate was able to reduce food intake in both diet groups (P <0.05). Fur- ture, fasting glucose levels were significantly lower in both topiramate groups than placebo groups (P <0.05), and serum leptin levels in the HFD group were decreased (P <0.05). Additionally, there was no significant difference in serum levels of triglycerides, free fatty acids, or insulin between the four groups. Conclusion : Topiramate significantly inhibited body weight gain by reducing food intake, especially in the HFD group and reduced serum levels of glucose in both diet groups and of leptin in the HFD group.